Lilly starts a Phase 2 trial of macupatide and eloralintide in adults with obesity and type 2 diabetes
CombinationP1Primary public evidenceTrial registry record
NCT07215559 lists a start date of 16 October 2025. It is a Phase 2 placebo-controlled study of macupatide and eloralintide, alone or in combination, in adults with obesity or overweight and type 2 diabetes. The registry lists 200 planned participants, 42 locations and a primary completion date of March 2027.
200
Planned participants, as recorded in the registry
March 2027
Primary completion date listed in the registry
Background and context
What is compared
This Phase 2 study tests macupatide and eloralintide, alone and together, against placebo, double-blind, in adults with obesity or overweight and type 2 diabetes. The primary endpoint is percent change in body weight from baseline to week 32, and participation lasts about 48 weeks.
Who can take part
Adults aged 18 to 75 need type 2 diabetes with an HbA1c from 7.5% to 10.5%, treated with diet and exercise, metformin or an SGLT2 inhibitor for at least three months. They also need a stable body weight and a BMI of at least 27. The record excludes insulin use in the past year. Sites are in the United States, Argentina, Australia and Puerto Rico.
Where it stands
The study is no longer recruiting and no results are posted. HbA1c, BMI and fasting glucose are secondary measures at week 32. Macupatide is part of every active arm except eloralintide alone, so any later result has to be read arm by arm.
Trial record: ClinicalTrials.gov NCT07215559, read on 2026-10-15. Registered plans can change.
P1Primary public evidenceTrial registry record.An official trial registration. A registration shows that a study exists; it does not show that the compound works.
